trending Market Intelligence /marketintelligence/en/news-insights/trending/FD8JBoQw-atVD6EtQ4221Q2 content esgSubNav
In This List

Protagonist Therapeutics appoints director

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Protagonist Therapeutics appoints director

Protagonist Therapeutics, Inc. appointed Sarah Noonberg to the board, replacing Julie Grant.

Noonberg is the chief medical officer of Prothena Corp. plc. Grant, who has stepped down from the board, is a partner at Canaan Partners.